PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PCI Pharma Services Appoints New Chief Financial Officer, SVP, Serge Dupuis

Philadelphia, PA – 22 March, 2019. Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer (CFO). 

Serge’s appointment supports PCI’s continued strategic growth and expansion across its global network, currently spanning 20 facilities in eight locations across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.

Serge brings to PCI more than 20 years’ experience in senior leadership roles, mainly in manufacturing environments. He joins the organization from CSP Technologies where he held the role of CFO. Prior to this, Serge served in significant senior-level roles with a range of internationally-recognized manufacturing and services, logistics and defense companies.

In welcoming Serge to PCI, Chief Executive Officer Salim Haffar said: “We are delighted Serge is joining us during this transformative time in PCI’s growth. His appointment is significant; confirming our long-standing commitment to partnering with leading pharmaceutical and biotech companies and help bring their life-saving medicines to patients around the world. Our trusted relationships with our customers are at the heart of all we do; our strategic growth plan, backed by robust global investment, reflects this. Serge will play an invaluable role as we build new capabilities and capacity, supported by innovative technology and first-class equipment – ensuring PCI continues to deliver outstanding quality and service for our clients in both established and emerging global markets.”

Serge added: “I am excited to join the PCI organization, a very successful and unique leader in the pharmaceutical and biotech industry. I believe that PCI is very well-positioned and has a tremendous growth potential based on the impressive reputation, depth of knowledge and sizeable investment.”

PCI recently expanded operations through acquisition, adding key locations in San Diego, Dublin and Melbourne, as well as announcing a record year for capital investment across its global business.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026